Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
International Journal of Medicinal Mushrooms
Fator do impacto: 1.423 FI de cinco anos: 1.525 SJR: 0.431 SNIP: 0.661 CiteScore™: 1.38

ISSN Imprimir: 1521-9437
ISSN On-line: 1940-4344

Volume 22, 2020 Volume 21, 2019 Volume 20, 2018 Volume 19, 2017 Volume 18, 2016 Volume 17, 2015 Volume 16, 2014 Volume 15, 2013 Volume 14, 2012 Volume 13, 2011 Volume 12, 2010 Volume 11, 2009 Volume 10, 2008 Volume 9, 2007 Volume 8, 2006 Volume 7, 2005 Volume 6, 2004 Volume 5, 2003 Volume 4, 2002 Volume 3, 2001 Volume 2, 2000 Volume 1, 1999

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v9.i1.40
pages 29-38

Potential Benefits of Ling Zhi or Reishi Mushroom Ganoderma lucidum (W. Curt.: Fr.) P. Karst. (Aphyllophoromycetideae) to Breast Cancer Patients

Alice W. Chen
Specialty Mushrooms, 1730 Penfield Rd., No.41, Penfield, NY 14526, USA
John Seleen
Mushroom Science Laboratory, JHS Natural Products, P.O. Box 50398, Eugene, OR 97405, USA


We present a model case study of a stage IIIa breast cancer patient adapting to the adjuvant use of Ganoderma lucidum in conjunction with a standard regimen of breast cancer treatments (presurgery ACT chemotherapy, surgery, radiotherapy, and postsurgery chemoprevention). According to the personal account of the authors of this research, G. lucidum triterpene-enriched polysaccharide extract of a new hybrid, Reishi Gano 161, containing 12% β-D-glucan and 6% triterpenes, was beneficial to the patient in numerous ways, such as effective tumor shrinkage, minimal or transient side effects from chemotherapy and radiotherapy, and improvement of the quality of life, compared to the experience of patients who used only conventional cancer treatments. New studies unveiled the molecular mechanism of the antitumor activity of this legendary medicinal mushroom, which appeared to be based on the inhibition of the nuclear transcription factor, NF-kappaB (NF-κB). NF-κB is overexpressed in various cancer cell lines and can serve as a molecular target for the development of more precise chemoprevention and anticancer therapy.